These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 22027417)

  • 1. [When CRAF takes over BRAF in melanoma].
    Dumaz N; Bagot M; Bensussan A
    Med Sci (Paris); 2011 Oct; 27(10):817-9. PubMed ID: 22027417
    [No Abstract]   [Full Text] [Related]  

  • 2. Newer developments in the immunotherapy of malignant melanoma.
    Maslin B; Alexandrescu DT; Ichim TE; Dasanu CA
    J Oncol Pharm Pract; 2014 Feb; 20(1):3-10. PubMed ID: 23435643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Anti-CTLA-4 monoclonal antibody: a major step in the treatment of metastatic melanoma].
    Robert C; Mateus C
    Med Sci (Paris); 2011 Oct; 27(10):850-8. PubMed ID: 22027422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunostimulatory Monoclonal Antibodies and Immunomodulation: Harvesting the Crop.
    Berraondo P; Ochoa MC; Rodriguez-Ruiz ME; Minute L; Lasarte JJ; Melero I
    Cancer Res; 2016 May; 76(10):2863-7. PubMed ID: 27308833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Somatic mutations and immunotherapy outcome with CTLA-4 blockade in melanoma.
    Boussiotis VA
    N Engl J Med; 2014 Dec; 371(23):2230-2. PubMed ID: 25409261
    [No Abstract]   [Full Text] [Related]  

  • 6. How should we use anti-CTLA-4 antibodies?
    Marabelle A; Eggermont A
    Eur J Cancer; 2015 Nov; 51(17):2686-8. PubMed ID: 26613660
    [No Abstract]   [Full Text] [Related]  

  • 7. Melanoma immunotherapy: historical precedents, recent successes and future prospects.
    Raaijmakers MI; Rozati S; Goldinger SM; Widmer DS; Dummer R; Levesque MP
    Immunotherapy; 2013 Feb; 5(2):169-82. PubMed ID: 23413908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to "Ipilimumab (Yervoy) and the TGN1412 catastrophe".
    Curran MA; Callahan MK; Subudhi SK; Allison JP
    Immunobiology; 2012 Jun; 217(6):590-2. PubMed ID: 22459268
    [No Abstract]   [Full Text] [Related]  

  • 9. Therapeutic use of anti-CTLA-4 antibodies.
    Blank CU; Enk A
    Int Immunol; 2015 Jan; 27(1):3-10. PubMed ID: 25038057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.
    Vétizou M; Pitt JM; Daillère R; Lepage P; Waldschmitt N; Flament C; Rusakiewicz S; Routy B; Roberti MP; Duong CP; Poirier-Colame V; Roux A; Becharef S; Formenti S; Golden E; Cording S; Eberl G; Schlitzer A; Ginhoux F; Mani S; Yamazaki T; Jacquelot N; Enot DP; Bérard M; Nigou J; Opolon P; Eggermont A; Woerther PL; Chachaty E; Chaput N; Robert C; Mateus C; Kroemer G; Raoult D; Boneca IG; Carbonnel F; Chamaillard M; Zitvogel L
    Science; 2015 Nov; 350(6264):1079-84. PubMed ID: 26541610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained clinico-radiologic response to anti-cytotoxic T lymphocyte antigen 4 antibody therapy in metastatic myxoid liposarcoma.
    Dasanu CA
    J Oncol Pharm Pract; 2017 Oct; 23(7):549-551. PubMed ID: 27511215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Not Available].
    Mateus C; Libenciuc C; Robert C
    Bull Cancer; 2016 Jun; 103(6 Suppl 1):S4-S11. PubMed ID: 27494973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations.
    Camacho LH
    Cancer Med; 2015 May; 4(5):661-72. PubMed ID: 25619164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IMMUNOTHERAPY. Could microbial therapy boost cancer immunotherapy?
    Snyder A; Pamer E; Wolchok J
    Science; 2015 Nov; 350(6264):1031-2. PubMed ID: 26612936
    [No Abstract]   [Full Text] [Related]  

  • 15. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
    Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
    Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.
    Graziani G; Tentori L; Navarra P
    Pharmacol Res; 2012 Jan; 65(1):9-22. PubMed ID: 21930211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management.
    Savoia P; Astrua C; Fava P
    Hum Vaccin Immunother; 2016 May; 12(5):1092-101. PubMed ID: 26889818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breakthrough of the year 2013. Cancer immunotherapy.
    Couzin-Frankel J
    Science; 2013 Dec; 342(6165):1432-3. PubMed ID: 24357284
    [No Abstract]   [Full Text] [Related]  

  • 19. Immunotherapy for the Treatment of Uveal Melanoma: Current Status and Emerging Therapies.
    Komatsubara KM; Carvajal RD
    Curr Oncol Rep; 2017 Jul; 19(7):45. PubMed ID: 28508938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Systemic treatment of melanoma brain metastases].
    Le Rhun É; Mateus C; Mortier L; Dhermain F; Guillot B; Grob JJ; Lebbe C; Thomas M; Jouary T; Leccia MT; Robert C
    Cancer Radiother; 2015 Feb; 19(1):48-54. PubMed ID: 25656856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.